Live
Aspen Pharmacare Holdings Limited
1260 candles · 5Y · retrieved
Estimated fair value
80.36
Range
62.62–111.74
Price vs value
803% below
Model support
Value
803% below fair value
confidence low
Estimate momentum
tracking
trends after ~30 days
Next catalyst
none scheduled
Volatility
—
building depth
1M forecast
withheld
Value tells you the size of the gap; the other cells tell you what could close it — and when. A cheap stock without a catalyst can stay cheap.
No forecasts reference APNHF in the active snapshot. Forecast slots populate as engines cover this instrument.
No intelligence items published yet.
Price trades 803% below the fair-value estimate — APNHF screens as materially undervalued. The 3 models disagree widely (dispersion 84.8%) — treat the range, not the midpoint, as the answer. A valuation gap is not a timing signal and currently has zero ranking weight.
Forward earnings lens
0.7x FY2027 P/E
EPS 12.47+109.3%1 analysts
Shown as context, not blended into fair value, while genuine point-in-time forward-multiple history accumulates.
Where estimates sit vs price 8.90
Total payout (dividends + net buybacks): not shown — no recurring shareholder payout is available.
Not meaningful for this company type: excess returns model (financials), path-to-profitability (scenario), dividend discount model, p/ocf vs peer reits (ffo proxy).
Cheap or expensive — depending on the yardstick
Entry threshold
below 64.29(fair value 80.36 − 20%)
price is inside your band
A valuation threshold, not a timing signal — a cheap stock can keep falling. Alerts wire in when the notification substrate lands.
Estimate revisions: tracking since 2026-09-03 — trends appear after ~30 days of snapshots.
Company profile at a glance
Bars are scaled to documented anchors (e.g. 35% operating margin = full bar), not ranked against other companies. Each row stands on its own — there is no hidden total score.
Financials at a glance· latest reported year · 8y of statements
Revenue
$35.0B
-1% per year over the period
Operating margin
15.5%
5y average 15.2%
Free cash flow
—
Net debt / EBITDA
-1.8×
net cash position
ROE
3.4%
net income ÷ equity
ROIC
6.2%
after-tax operating profit ÷ capital
Where the revenue dollar went · FY2026
What the current price is assuming
No revenue-growth or margin assumption inside the model's sanity bounds justifies today's price of 8.90. Either the market expects something far outside historical experience, or the price has detached from fundamentals.
What the DCF is made of — present value by year (base case)
Which growth × margin combinations justify today's price
| margin ↓ / growth → | -5% | 0% | 5% | 10% | 15% | 20% | 25% | 30% | 35% | 40% |
|---|---|---|---|---|---|---|---|---|---|---|
| 60% | ||||||||||
| 55% |
Price vs fair value through time
Fair value if assumptions move — discount rate × terminal growth
| discount rate ↓ | g 0% | g 1% | g 2% | g 3% | g 4% |
|---|---|---|---|---|---|
| 6.1% | 183.52 | 185.29 | 187.92 | 192.26 | 200.73 |
| 6.6% | 165.9 | 165.6 | 165.17 | 164.5 | 163.31 |
| 7.1% |
Terminal value is 84% of the total. Solid years are consensus-anchored; lighter years fade to the stable rate.
| 50% |
|---|
| 45% |
|---|
| 40% |
|---|
| 35% |
|---|
| 30% |
|---|
| 25% |
|---|
| 20% |
|---|
| 15% |
|---|
| 10% |
|---|
| 5% |
|---|
| 0% |
|---|
Sage cells are the assumption pairs that make the model value equal today's price (±2%) — none inside these bounds — the price asks for more than this grid allows.
— price · — fair value (band = bear–bull). Vintages accumulating since 2026-09-02 (recorded at compute time; no historical backfill).
| 150.97 |
| 149.32 |
| 147.03 |
| 143.61 |
| 138 |
| 7.6% | 138.19 | 135.67 | 132.26 | 127.36 | 119.74 |
|---|
| 8.1% | 127.15 | 124.09 | 120.03 | 114.38 | 105.97 |
|---|
| 8.6% | 117.53 | 114.16 | 109.76 | 103.78 | 95.21 |
|---|
| 9.1% | 109.11 | 105.57 | 101.02 | 94.99 | 86.59 |
|---|
Cells compare each implied fair value with the current price 8.9: green above it, burgundy below. Outlined cell = base case.